We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Digital Outsert | Jan 2024

Clareon® Collection | Featuring J. Morgan Micheletti, MD

When it comes to the IOLs in his armamentarium, J. Morgan Micheletti, MD, knows what matters most.

Whether I utilize AutonoMe or the Monarch injector, the Clareon® platform consistently exhibits a smooth and efficient deployment. This attribute notably ranks it among the fastest opening IOLs in my armamentarium.1

The first time I saw one of my Clareon® patients postoperatively, it was truly astounding. The lens is so clear,2,3 it was actually a challenge to see the lens at the slit lamp, which is remarkable.

As a surgeon, the best thing I can hear is how happy a patient is with their vision. That’s exactly what I’ve experienced with patients in whom I’ve implanted the Clareon® IOL.

See future issues and “Clareon® Collection of IOLs” on Eyetube to hear from more surgeons.

Important Product Information – Clareon Aspheric Hydrophobic Acrylic IOL with the AutonoMe Automated Pre-loaded Delivery System

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

INDICATION: The Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed.


The Clareon IOL is intended for implantation in the capsular bag only. Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: Patients in whom the posterior capsule is ruptured, zonules are damaged, or primary posterior capsulotomy is planned.

DO NOT re-sterilize the Clareon IOL or the AutonoMe Delivery System by any method. DO NOT implant the IOL if the sterility has been compromised or if the sterile package has been unintentionally opened before use. DO NOT reuse the Clareon IOL or AutonoMe Delivery System. The device is for single use only.

The safety and effectiveness of the Clareon IOL has not been substantiated in clinical trials in patients with certain pre-existing conditions and/or intraoperative conditions (listed in Tables 4 and 5 of the Directions for Use).

As with any surgical procedure, there is risk involved. Potential complications accompanying cataract and/or IOL implantation surgery may include, but are not limited to, the following: lens epithelial cell on-growth, corneal endothelial cell damage, infection (endophthalmitis), toxic anterior segment syndrome (TASS), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, anterior uveitis, hyphema, pigment dispersion, posterior capsule opacification, transient or persistent glaucoma, and secondary surgical interventions. Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.

ATTENTION: Refer to the Directions for Use labeling for a complete list of indications, warnings and precautions.

1. Clareon Toric Aspheric Hydrophobic Acrylic IOL with the AutonoMe DFU

2. Clareon IOL Aspheric Hydrophobic Acrylic IOL Monofocal DFU

3. Lehmann R, et al. Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample. Clin Ophthalmol. 2021;15:1647-1657.

© 2023 Alcon Inc. 01/24 US-CLV-2300029

Clareon trademark information. All other brand/product names are the trademarks of their respective owners.